EMFAT
ACAD icon

Emerald Mutual Fund Advisers Trust’s Acadia Pharmaceuticals ACAD Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,576
Closed -$369K – 198
2026
Q1 		$369K Sell
16,576
-467,930
-97% -$11.2M 0.02% 172
2025
Q4 		$12.9M Buy
484,506
+169,182
+54% +$4.04M 0.63% 70
2025
Q3 		$6.73M Sell
315,324
-3,982
-1% -$94.2K 0.35% 99
2025
Q2 		$6.89M Sell
319,306
-175,778
-36% -$3.27M 0.42% 88
2025
Q1 		$8.22M Sell
495,084
-5,307
-1% -$96.4K 0.58% 69
2024
Q4 		$9.18M Sell
500,391
-74,419
-13% -$1.2M 0.56% 70
2024
Q3 		$8.84M Buy
574,810
+15,961
+3% +$266K 0.46% 76
2024
Q2 		$9.08M Sell
558,849
-691,380
-55% -$11.2M 0.48% 78
2024
Q1 		$23.1M Sell
1,250,229
-54,327
-4% -$1.35M 1.2% 24
2023
Q4 		$40.8M Buy
1,304,556
+568
+0% +$13.6K 2.16% 1
2023
Q3 		$27.2M Buy
1,303,988
+12,894
+1% +$350K 1.64% 9
2023
Q2 		$30.9M Buy
1,291,094
+83,792
+7% +$1.86M 1.68% 4
2023
Q1 		$22.7M Buy
1,207,302
+158,552
+15% +$3.02M 1.34% 17
2022
Q4 		$16.7M Buy
1,048,750
+16,011
+2% +$250K 1.03% 39
2022
Q3 		$16.9M Buy
1,032,739
+265,768
+35% +$4.3M 1.07% 30
2022
Q2 		$10.8M Buy
766,971
+116,978
+18% +$2.18M 0.63% 64
2022
Q1 		$15.7M Sell
649,993
-57,976
-8% -$1.4M 0.7% 57
2021
Q4 		$16.5M Buy
+707,969
New +$14.2M 0.58% 66

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's ACAD Position: Q2 2026 in Review

Emerald Mutual Fund Advisers Trust sold out of Acadia Pharmaceuticals (ACAD) in Q2 2026, closing a stake of 16,576 shares — an estimated $369K sold.

Emerald Mutual Fund Advisers Trust first reported a position in ACAD in Q4 2021 and held it in 18 quarters. The position peaked at $40.8M in Q4 2023. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Emerald Mutual Fund Advisers Trust reported no remaining Acadia Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 16,576 Acadia Pharmaceuticals shares in Q2 2026, an estimated $369K.
  • Emerald Mutual Fund Advisers Trust first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 18 quarters.
  • Emerald Mutual Fund Advisers Trust's Acadia Pharmaceuticals position peaked at $40.8M in Q4 2023.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q2 2026, filed 5 Aug 2026.